Juan A. Cámara

University of California, San Francisco

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Veronica Steri

University of California, San Francisco

Irene Chicote

Vall d'Hebron Institute of Oncology

Héctor G. Pálmer

Centro de Investigación Biomédica en Red de Cáncer

Jordi Martínez‐Quintanilla

Centro de Investigación Biomédica en Red de Cáncer

McAllister Milly

Manuela Gariboldi

Fondazione IRCCS Istituto Nazionale dei Tumori

Jorge Barriuso

Cancer Research UK Manchester Institute

Lara Nonell

Vall d'Hebron Institute of Oncology

Raquel Flores

Vall d'Hebron Institute of Oncology

Débora Cabot

Vall d'Hebron Institute of Oncology

Cooperative Institutions

University of California, San Francisco

114

UCSF Helen Diller Family Comprehensive Cancer Center

Instituto de Salud Carlos III

Spanish National Cancer Research Centre

Universitat Autònoma de Barcelona

Centro de Investigación del Cáncer

University of California System

Consejo Superior de Investigaciones Científicas

Vall d'Hebron Institute of Oncology

Centro de Investigación Biomédica en Red

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Eedcontrols craniofacial osteoblast differentiation and mesenchymal proliferation from the neural crest

bioRxiv (Cold Spring Harbor Laboratory) (2024)

Tim Casey-Clyde Siyuan Liu Juan A. Cámara Camilla S. Teng Yoon‐Gu Jang

The histone methyltransferase Polycomb repressive complex 2 (PRC2) is required for specification of the neural crest, and mis-regulation of neural crest development can cause severe congenital malformations. PRC2 is necessary for neural crest induction, but the embryonic, cellular, and molecular consequences of PRC2 activity after neural crest induction are incompletely understood. Here we show that

Crest

10.1101/2024.03.13.584903

Cite

Citations (0)

Preclinical Development and Characterization of Humanized Anti-CD72 Nanobody Chimeric Antigen Receptor T Cells for B Cell Malignancies

Transplantation and Cellular Therapy (2024)

William C. Temple Adila Izgutdina Matthew A. Nix Benjamin J. Huang Paul Phojanakong

10.1016/j.jtct.2023.12.226

Cite

Citations (0)

Supplementary Table 4 from Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei

Jordi Martínez‐Quintanilla Débora Cabot Doménico Sabia Oriol Arqués Jordi Vergés

Supplementary Table 4. Correlation of PMP markers in patient samples and their corresponding organoid model.

Pseudomyxoma Peritonei

Table (database)

Precision oncology

10.1158/1078-0432.27013736

Cite

Citations (0)

Figure 3 from Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei

Jordi Martínez‐Quintanilla Débora Cabot Doménico Sabia Oriol Arqués Jordi Vergés

Treatment with BRAF inhibitor is enough to block RAS/ERK signaling pathway and reduce cell viability in PMP models. BRAFWT (T70) or BRAFV600E (CTAX34) colorectal cancer PDXO and BRAFV600E PMP PDXO (PMP5.1) or PDO (PMP5.2) derived from two different peritoneal metastasis from PMP patient 5 treated with vehicle, mitomycin C 150 ng/mL, cetuximab 100 μg/mL, encorafenib 1 μmol/L, doublet (encorafenib + cetuximab). A and B, Cell viability (A) and caspase 3/7 activation (B) were measured after 5 days or 48 hours on treatment, respectively. Mean ± SD of triplicates is shown. Significant differences were assessed using one-way ANOVA and Dunnett’s multiple comparisons tests compared to control (*, P value < 0.05; **, P value < 0.01; ***, P value < 0.001; ****, P value < 0.0001). C and D, Western blot analysis of phospho-ERK, phospho-EGFR, ERK, and EGFR was performed after 30 minutes or 24 hours on treatment. Quantification of phospho-EGFR/EGFR (C) and phospho-ERK/ERK (D) ration in all the samples. r.u, relative units. PMP, Pseudomyxoma peritonei; CRC, Colorectal cancer; PDO, Patient-derived organoid; PDXO, Patient-derived xenografts organoid.

Pseudomyxoma Peritonei

Systemic therapy

Targeted Therapy

Precision oncology

10.1158/1078-0432.27013787

Cite

Citations (0)

Supplementary Figure 4 from Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei

Jordi Martínez‐Quintanilla Débora Cabot Doménico Sabia Oriol Arqués Jordi Vergés

Supplementary Figure 4. BRAF inhibitor reduces Phospho-ERK in BRAFV600E mutant PMPPDO and PDXO models in a dose dependent manner.

Pseudomyxoma Peritonei

10.1158/1078-0432.27013766.v1

Cite

Citations (0)

The chronology of the defensive systems at Los Millares (Santa Fe de Mondújar, Almería, Spain)

Archaeopress Publishing Ltd eBooks (2020)

Fernando Ricardo Molina González José Andrés Afonso Marrero Juan A. Cámara Alberto Dorado Alejos Rafael María Martínez Sánchez

Chronology

Almeria

10.2307/jj.15136001.8

Cite

Citations (5)

Nanoceria as Safe Contrast Agents for X-ray CT Imaging

Nanomaterials (2023)

Ana García Juan A. Cámara Ana Boullosa Muriel F. Gustà Laura Mondragón

Cerium oxide nanoparticles (CeO2NPs) have exceptional catalytic properties, rendering them highly effective in removing excessive reactive oxygen species (ROS) from biological environments, which is crucial in safeguarding these environments against radiation-induced damage. Additionally, the Ce atom's high Z number makes it an ideal candidate for utilisation as an X-ray imaging contrast agent. We herein show how the injection of albumin-stabilised 5 nm CeO2NPs into mice revealed substantial enhancement in X-ray contrast, reaching up to a tenfold increase at significantly lower concentrations than commercial or other proposed contrast agents. Remarkably, these NPs exhibited prolonged residence time within the target organs. Thus, upon injection into the tail vein, they exhibited efficient uptake by the liver and spleen, with 85% of the injected dose (%ID) recovered after 7 days. In the case of intratumoral administration, 99% ID of CeO2NPs remained within the tumour throughout the 7-day observation period, allowing for observation of disease dynamics. Mass spectrometry (ICP-MS) elemental analysis confirmed X-ray CT imaging observations.

10.3390/nano13152208

Cite

Citations (9)

Supplementary Figure S14 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer

Niranjan Meher Anil P. Bidkar Anju Wadhwa Kondapa Naidu Bobba Suchi Dhrona

Supplementary Figure S14. Autoradiographic images and H&E staining images of PDX LTL-545 tumor sections from day 1 to day 4 post injection of 89Zr labeled nanocarriers.

Nanocarriers

10.1158/1535-7163.28122795

Cite

Citations (0)

Supplementary Figure S12 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer

Niranjan Meher Anil P. Bidkar Anju Wadhwa Kondapa Naidu Bobba Suchi Dhrona

Supplementary Figure S12. Autoradiographic images and H&E staining images of subcutaneous 22rv1 tumor sections from day 1 to day 4 post injection of 89Zr labeled nanocarriers. *Indicate the presence of necrosis.

Nanocarriers

PET Imaging

10.1158/1535-7163.28122804

Cite

Citations (0)

Supplementary Table S15 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer

Niranjan Meher Anil P. Bidkar Anju Wadhwa Kondapa Naidu Bobba Suchi Dhrona

Supplementary Table S15. Organ biodistribution analysis data in %ID/g tissue for 89Zr labeled nanocarriers at 96 h in metastatic mice model with 22rv1 cell inoculated in kidney capsule tumors. (n = 4)

Nanocarriers

Table (database)

10.1158/1535-7163.28122714

Cite

Citations (0)